Psoriatic Arthritis

Approximately 125 million people worldwide, including more than 8 million Americans, have psoriasis, according to the National Psoriasis Foundation. Between 10% and 30% of these patients will also develop psoriatic arthritis.

Relying primarily on patient global assessments falls short in determining comprehensive disease severity, but by adding the Skindex instrument or other measures, clinicians may obtain a better evaluation of patient quality of life, according to a panel of stakeholders on behalf of the International Dermatology Outcome Measures and the American Academy of Dermatology.

Learning Objectives:

As half of all pregnancies go unplanned, patients and providers must understand the implications of therapeutic options in all women with psoriasis who are sexually active, whether or not they plan to start a family, according to researchers.

Women of childbearing age with rheumatic diseases worldwide fail to receive appropriate information about the family planning and pregnancy continuum, according to findings presented at EULAR 2019. Healio Rheumatology took a closer look at the data and sat down with several key opinion leaders for a roundtable discussion to gain deeper understanding of how to resolve these issues.

Consistent follow-up visits with the same physician and treatment with subcutaneous or IV drugs are associated with better patient-reported experiences among those with inflammatory arthritis, according to findings published in the Journal of Clinical Rheumatology.

Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.

The FDA has extended approval for ixekizumab injection 80 mg/mL to treat adults with ankylosing spondylitis – or radiographic axial spondyloarthritis - according to an Eli Lilly press release.

HILTON HEAD, S.C. — In a duet session focused on spondyloarthritis, Grace Wright, MD, PhD, and Reeti Joshi, MD, detailed the differences between axial and peripheral disease and identified the various features of both in an effort to aid early diagnosis.

Taltz met the primary and secondary endpoints at week 12 in a phase 4 head-to-head study comparing its efficacy and safety vs. Tremfya in patients with moderate to severe plaque psoriasis, according to an announcement from Eli Lilly and Company.